Business
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
ALAMEDA, Calif., March 12, 2025--Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current an
About this update from Vivani Medical, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/f02ce9c20ff1643886e1d479f5cba3d5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I4mla7zczWeA9Nrn0vXJKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f02ce9c20ff1643886e1d479f5cba3d5","width":480,"height":480}},"lazy":false},{"type":"text","content":"Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"Cortigent’s Orion® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results","length":185,"tagName":"p","attribs":{}},{"type":"text","content":"Formerly Second Sight Medical Products, Cortigent achieved the first and only FDA authorization (under a Humanitarian Device Exemption) for an artificial vision device called the Argus® II, which was marketed for a rare form of blindness and implanted in hundreds of patients","length":275,"tagName":"p","attribs":{}},{"type":"text","content":"Cortigent’s precision neurostimulation technology is also being developed for the recovery of arm and hand motion in paralysis due to stroke","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"Spin-off will allow Vivani to focus on developing miniature, ultra long-acting GLP-1 implants for chronic weight management and type 2 diabetes with once or twice-yearly administration","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"ALAMEDA, Calif., March 12, 2025--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise.","length":603,"tagName":"p"},{"type":"...